Non-technological barriers to the diffusion of energy-efficient HVAC&R solutions in the food retail sector

SuperSmart is an European Union (EU) project aiming at speeding up the uptake of energy-efficient re- frigeration, heating and cooling solutions for Europe\u2019s food retail sector, reducing its energy use, lowering its environmental footprint and increasing its economic benefits. The project pursues the removal of non- technological barriers to efficient heating & cooling in the European food retail sector and supports the introduction of a new EU Ecolabel for food retail stores. Non-technological barriers have been mapped and categorized by preliminary interviewing food re- tail sector stakeholders. While highlighting a general positive attitude towards energy efficiency of the sector stakeholders, the results of the survey reveal the need for specific actions focused on improving the knowledge level of technical staff, from the planning and design stage down to servicing and main- tenance. Raising awareness about available technology and financial support is also required. In general terms, barriers are always perceived as stronger when moving North to South, and West to East in Europe, thus emphasizing the need for homogenization of virtuous practices and attitudes throughout Europ

Monitoring Of a Commercial Refrigeration CO2 System And Comparison With Simulations

The demand for natural refrigerants is growing in commercial refrigeration systems. In the recent years, carbon dioxide has increased its market share in the field of commercial refrigeration and has proven to be a viable solution for the replacement of hydrofluorocarbon (HFC) systems. This success is mainly due to the ongoing technological evolution of carbon dioxide refrigeration systems. In the present paper, a CO2 commercial refrigeration unit serving a supermarket located in Northern Italy is presented. The unit consists of a booster compressor rack with parallel compression, with ten compressors arranged to provide around 20 kW cooling capacity at low temperature and 90 kW cooling capacity at medium temperature. Four out of ten compressors, provided by Frascold®, are arranged in parallel. The installation, in addition to the cooling load, provides all the thermal functions in one unit: it integrates a heat exchanger for the air conditioning and the possibility of two stage heat recovery, for sanitary hot water production and for space heating. The refrigeration unit is equipped with pressure and temperature sensors, power consumption and load analysers for the compressors. A computer model has been developed to evaluate the acquired data of the system and to analyse the key parameters. The preliminary results from the monitoring of this unit are presented in this paper and used to calibrate the model of the system. Afterwards, simulations have been performed at variable operating conditions in a cold month to evaluate the performance of the unit. The results of the model have been compared to an independent set of monitoring data

Innovative reheat approach of the TES system during the hotel’s standstill operation utilizing a CO2 heat pump/chiller unit

The implementation of CO2 as a refrigerant is considered one of the solutions to improve the overall building’s energy performance, especially if the heat recovery concept is applied. In this paper, an innovative approach to compensate for the thermal losses of the in-series stratified thermal energy storage (TES) tanks during periods with insignificant Domestic Heating Water (DHW) demands is numerically investigated using Modelica language. The approach adopts a CO2 heat pump/chiller unit with two water-cooled gas coolers and an air-cooled gas cooler in the case of cooling only is required. The flow leaving one of the middle tanks is mixed with the flow leaving the first gas cooler and the mixture is heated up through the second gas cooler to the heating setpoint and circulated back to the TES system. Results have shown improvements in the thermal charging efficiency, while the system COP has reached 5.5 compared to 4.4 if the reheating approach is not adopted. TIL, Modelica Buildings, and Modelica standards libraries were used to develop the model. Keywords: Thermal Energy Storage, CO2, Heat Pump, chiller, ModelicaInnovative reheat approach of the TES system during the hotel’s standstill operation utilizing a CO2 heat pump/chiller unitacceptedVersio

Experimental evaluation of the performance of an ejector for a single compression multi-temperature CO2 refrigeration unit

A novel vapor-compression system concept employing carbon dioxide as the refrigerant is proposed to serve the needs of a typical medium-size refrigerated truck used for multi-temperature (MT and LT) goods delivery. The system design is based on the implementation of an ejector as the only component increasing the refrigerant pressure from the LT evaporation pressure to the MT evaporation pressure, thus allowing the realization of a unit providing cooling effect at two different temperature levels with only one stage of compression. The ejector was experimentally tested in order to evaluate its ability to effectively entrain mass flow rate from very low pressure conditions at the suction nozzle, corresponding to the LT evaporator outlet conditions. In addition, a simple preliminary thermodynamic evaluation of tExperimental evaluation of the performance of an ejector for a single compression multi-temperature CO2 refrigeration unitacceptedVersio

A novel R744 multi-temperature cycle for refrigerated transport applications with low-temperature ejector: Experimental ejector characterization and thermodynamic cycle assessment

A novel vapor-compression system concept employing carbon dioxide as the refrigerant is proposed to serve the needs of a typical medium-size refrigerated truck used for multi-temperature (MT and LT) goods delivery. The system design is based on the implementation of an ejector as the only component increasing the refrigerant pressure from the LT evaporation pressure to the MT evaporation pressure, thus providing cooling effect at two different temperature levels with only one stage of compression. The ejector was experimentally tested and its ability to effectively entrain mass flow rate from low pressure suction conditions (corresponding to a LT evaporation temperature of −25 °C) was assessed. Lower external ambient temperatures and consequent lower expansion energy available at the ejector motive nozzle leads to a reduction of the maximum achievable pressure lift. Moreover, a significant degradation of the ejector performance towards the highest pressure lifts is experienced. Based on the ejector experimental data, a numerical evaluation of the proposed cooling unit performance has been performed, highlighting that in design conditions (LT evaporation at −25 °C) the cooling unit provides a LT freezing power ranging between 1.1 kW and 2.3 kW and a corresponding minimum MT cooling power ranging between 5.1 kW and 3.8 kW, depending on the chosen ejector lift. The MT cooling power can be further increased by increasing the compressor mass flow rate. The system COP is maximized at the maximum available lift provided by the ejector. © 2023 The AuthorsA novel R744 multi-temperature cycle for refrigerated transport applications with low-temperature ejector: Experimental ejector characterization and thermodynamic cycle assessmentpublishedVersio

Harnessing NK Cells for Cancer Treatment

In the last years, natural killer (NK) cell-based immunotherapy has emerged as a promising therapeutic approach for solid tumors and hematological malignancies. NK cells are innate lymphocytes with an array of functional competences, including anti-cancer, anti-viral, and anti-graft-vs.-host disease potential. The intriguing idea of harnessing such potent innate immune system effectors for cancer treatment led to the development of clinical trials based on the adoptive therapy of NK cells or on the use of monoclonal antibodies targeting the main NK cell immune checkpoints. Indeed, checkpoint immunotherapy that targets inhibitory receptors of T cells, reversing their functional blocking, marked a breakthrough in anticancer therapy, opening new approaches for cancer immunotherapy and resulted in extensive research on immune checkpoints. However, the clinical efficacy of T cell-based immunotherapy presents a series of limitations, including the inability of T cells to recognize and kill HLA-Ineg tumor cells. For these reasons, new strategies for cancer immunotherapy are now focusing on NK cells. Blockade with NK cell checkpoint inhibitors that reverse their functional block may overcome the limitations of T cell-based immunotherapy, mainly against HLA-Ineg tumor targets. Here, we discuss recent anti-tumor approaches based on mAb-mediated blocking of immune checkpoints (either restricted to NK cells or shared with T cells), used either as a single agent or in combination with other compounds, that have demonstrated promising clinical responses in both solid tumors and hematological malignancie

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which is impaired in heavily pre-treated HL patients. Here, we aimed to enhance the activity of early post-ASCT CI (nivolumab) administration with the infusion of autologous lymphocytes (ALI). Twelve patients with relapse/refractory (R/R) HL (median age 28.5 years; range 18-65), underwent lymphocyte apheresis after first line chemotherapy and then proceeded to salvage therapy. Subsequently, 9 patients with progressive disease at ASCT received early post-transplant CI supported with four ALI, whereas 3 responding patients received ALI alone, as a control cohort. No severe adverse events were recorded. HL-treated patients achieved negative PET scan CR and 8 are alive and disease-free after a median follow-up of 28 months. Four patients underwent subsequent allogeneic SCT. Phenotypic analysis of circulating cells showed a faster expansion of highly differentiated NK cells in ALI plus nivolumab-treated patients as compared to control patients. Our data show anti-tumor activity with good tolerability of ALI + CI for R/R HL and suggest that this setting may accelerate NK cell development/maturation and favor the expansion of the "adaptive" NK cell compartment in patients with HCMV seropositivity, in the absence of HCMV reactivation

Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study

The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) has significantly improved patients’ prognosis. Within the Campus ALL network we analyzed the outcome of adult Ph-ALL patients treated according to the GIMEMA LAL1913 protocol outside the clinical trial, to compare the real-life data with the study results. We included 421 consecutive patients, with a median age of 42 years. The complete remission (CR) rate after the first course of chemotherapy was 94% and a measurable residual disease (MRD) negativity after the third course was achieved in 72% of patients. The 3-year overall survival (OS) and disease-free survival (DFS) were 67% and 57%, respectively. In a multivariate analysis, MRD positivity negatively influenced DFS. In a time-dependent analysis including only very high risk (VHR) and MRD positive cases, transplanted (HSCT) patients had a significantly better DFS than non-HSCT ones (P=0.0017). During induction, grade ≥2 pegaspargase-related hepato-toxicity was observed in 25% of patients (vs 12% in the GIMEMA LAL1913 trial, P=0.0003). In this large real-life cohort of Ph-ALL, we confirmed the very high CR rate and a superimposable OS and DFS compared to the GIMEMA LAL1913 clinical trial: CR rate after C1 94% vs 85%, P=0.0004; 3-year OS 67% vs 67%, P=0.94; 3-year DFS 57% vs 63%, P=0.17. HSCT confirms its important role in VHR and MRD-positive patients. The rate of pegaspargase-related toxicity was significantly higher in the real-life setting, emphasizing the importance of dose adjustment in the presence of risk factors to avoid excessive toxicity

A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death

: The clinical manifestations of SARS-CoV-2 infection vary widely among patients, from asymptomatic to life-threatening. Host genetics is one of the factors that contributes to this variability as previously reported by the COVID-19 Host Genetics Initiative (HGI), which identified sixteen loci associated with COVID-19 severity. Herein, we investigated the genetic determinants of COVID-19 mortality, by performing a case-only genome-wide survival analysis, 60 days after infection, of 3904 COVID-19 patients from the GEN-COVID and other European series (EGAS00001005304 study of the COVID-19 HGI). Using imputed genotype data, we carried out a survival analysis using the Cox model adjusted for age, age2, sex, series, time of infection, and the first ten principal components. We observed a genome-wide significant (P-value < 5.0 × 10-8) association of the rs117011822 variant, on chromosome 11, of rs7208524 on chromosome 17, approaching the genome-wide threshold (P-value = 5.19 × 10-8). A total of 113 variants were associated with survival at P-value < 1.0 × 10-5 and most of them regulated the expression of genes involved in immune response (e.g., CD300 and KLR genes), or in lung repair and function (e.g., FGF19 and CDH13). Overall, our results suggest that germline variants may modulate COVID-19 risk of death, possibly through the regulation of gene expression in immune response and lung function pathways

Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features

The impact of common and rare variants in COVID-19 host genetics has been widely studied. In particular, in Fallerini et al. (Human genetics, 2022, 141, 147–173), common and rare variants were used to define an interpretable machine learning model for predicting COVID-19 severity. First, variants were converted into sets of Boolean features, depending on the absence or the presence of variants in each gene. An ensemble of LASSO logistic regression models was used to identify the most informative Boolean features with respect to the genetic bases of severity. After that, the Boolean features, selected by these logistic models, were combined into an Integrated PolyGenic Score (IPGS), which offers a very simple description of the contribution of host genetics in COVID-19 severity.. IPGS leads to an accuracy of 55%–60% on different cohorts, and, after a logistic regression with both IPGS and age as inputs, it leads to an accuracy of 75%. The goal of this paper is to improve the previous results, using not only the most informative Boolean features with respect to the genetic bases of severity but also the information on host organs involved in the disease. In this study, we generalize the IPGS adding a statistical weight for each organ, through the transformation of Boolean features into “Boolean quantum features,” inspired by quantum mechanics. The organ coefficients were set via the application of the genetic algorithm PyGAD, and, after that, we defined two new integrated polygenic scores (IPGSph1 and IPGSph2). By applying a logistic regression with both IPGS, (IPGSph2 (or indifferently IPGSph1) and age as inputs, we reached an accuracy of 84%–86%, thus improving the results previously shown in Fallerini et al. (Human genetics, 2022, 141, 147–173) by a factor of 10%